The peptide therapeutics market is expected to register a CAGR of 9.66% over the forecast period.
The COVID-19 pandemic substantially impacted the peptide therapeutics market. The pandemic surged the need for the development of novel peptides. In April 2022, an article published in the IJPRT journal reported the companies had developed peptide-based vaccines for COVID-19 treatment. Thus, initially, the growth of the peptide therapeutics market was driven by the increase in COVID-19 cases, as peptide therapeutics were reported efficacious for the treatment of Sars-CoV-2 infection. However, in the current scenario, as the pandemic has declined, the market may get negatively impacted. However, it is anticipated that with the efficacy of peptide therapeutics in treating other chronic diseases, the studied market will witness stable growth over the forecast period.
The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics.
Cancer cases are increasing worldwide. Globocan 2020 reported that by 2040, cancer cases worldwide are expected to increase by 56.7% of the current cancer cases. Studies have reported the significant results of peptide therapeutics in cancer treatment. For instance, in February 2021, an article published in the journal SCB reported that new-generation peptide therapeutics target cancer-specific signatures. Hence, they hold enormous potential for cancer therapy and diagnosis. Therefore, the increasing number of cancer cases and the significant effect of peptide therapeutics in cancer treatment is driving the growth of the studied market.
Also, the rising prevalence of some metabolic disorders, such as genetic disorders, organ dysfunction, and mitochondrial dysfunction, is fueling the growth of the studied market. Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by progressive glucocerebroside storage in macrophages, predominantly in bone, bone marrow, liver, and spleen. In July 2022, an article published in the journal JPHO asserted that the prevalence of GD in global birth was 1.5 cases per 100,000 live births. The overall global prevalence of GD was 0.9 cases per 100,000 inhabitants. The high prevalence of such metabolic disorders is fueling the demand for peptide therapeutics for treating metabolic disorders, thereby driving the growth of the studied market.
Furthermore, the technological development and introduction of new peptide therapeutics for treating chronic diseases like cancer are also fueling the growth of the studied market. In May 2021, ISSAR Pharmaceuticals decided to license out its peptide-based new NCEs with pre-IND filing and the United States patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes. Such developments are driving the growth of the studied market.
Therefore, the studied market is expected to witness significant growth over the forecast period due to the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.
The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment. For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed in the US in 2022. Thus, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period.
Furthermore, technological developments and new product launches are fueling the studied market's growth. In March 2022, BioNTech SE reported the expansion of its strategic collaboration with Regeneron to advance the Company's FixVaccandidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced NSCLC.
Moreover, the funding and investments for developing cancer vaccines are fueling this segment's growth. In September 2022, the Gastro-Intestinal Research Foundation (GIRF) in Chicago granted ElicioTherapeutics a USD 2.8 million grant to fund research for two therapeutic cancer vaccines. ELI-007 is being developed to target BRAF gene mutations, whereas ELI-008 is being designed to target p53 hotspot mutations in solid tumors, such as colorectal cancer, melanoma, and non-small cell lung cancer (NSCLC).
Thus, the segment is expected to witness significant growth over the forecast period due to the increasing number of cancer cases, technological developments, and the efficiency of peptide therapeutics in cancer treatment.
The high incidence of diseases such as cancer, CVDs, and diabetes creates demand for new biopharmaceuticals in the country. For instance, as per the Canadian Cancer Statistics 2021 released in November 2021, an estimated 229,200 Canadians were diagnosed with cancer. Thus, such high numbers of cancer cases are creating opportunities for new peptide therapeutics in the country and driving the studied market.
The rising prevalence of chronic diseases among the Mexican population is also expected to drive the market's growth. For instance, the IDF published in December 2021 estimated 14 million adults in Mexico living with diabetes. Peptides like amide (GLP-1) are effective in diabetes treatment. This is expected to raise the demand for peptide therapeutics, thereby contributing to the growth of the market in the region over the forecast period.
Furthermore, the rising government initiatives are also driving the growth of the studied market in the region. For instance, in February 2022, the Government of Nova Scotia province reported that Nova Scotians enrolled in Pharmacare programs that will begin switching to a biosimilar version of certain biologic drugs, including some insulins and medications, for treating Crohn's disease and rheumatism. More than 10,000 Canadians have safely switched to a biosimilar as part of this initiative. The increasing population using biosimilar drugs is also expected to contribute to the growth of the market in the region.
Thus, the rising awareness levels relating to peptide therapeutic products, technological advancements due to the presence of key market players, and rising cases of chronic diseases like cancer and diabetes are driving the growth of this market in the region over the forecast period.
This product will be delivered within 2 business days.
The COVID-19 pandemic substantially impacted the peptide therapeutics market. The pandemic surged the need for the development of novel peptides. In April 2022, an article published in the IJPRT journal reported the companies had developed peptide-based vaccines for COVID-19 treatment. Thus, initially, the growth of the peptide therapeutics market was driven by the increase in COVID-19 cases, as peptide therapeutics were reported efficacious for the treatment of Sars-CoV-2 infection. However, in the current scenario, as the pandemic has declined, the market may get negatively impacted. However, it is anticipated that with the efficacy of peptide therapeutics in treating other chronic diseases, the studied market will witness stable growth over the forecast period.
The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics.
Cancer cases are increasing worldwide. Globocan 2020 reported that by 2040, cancer cases worldwide are expected to increase by 56.7% of the current cancer cases. Studies have reported the significant results of peptide therapeutics in cancer treatment. For instance, in February 2021, an article published in the journal SCB reported that new-generation peptide therapeutics target cancer-specific signatures. Hence, they hold enormous potential for cancer therapy and diagnosis. Therefore, the increasing number of cancer cases and the significant effect of peptide therapeutics in cancer treatment is driving the growth of the studied market.
Also, the rising prevalence of some metabolic disorders, such as genetic disorders, organ dysfunction, and mitochondrial dysfunction, is fueling the growth of the studied market. Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by progressive glucocerebroside storage in macrophages, predominantly in bone, bone marrow, liver, and spleen. In July 2022, an article published in the journal JPHO asserted that the prevalence of GD in global birth was 1.5 cases per 100,000 live births. The overall global prevalence of GD was 0.9 cases per 100,000 inhabitants. The high prevalence of such metabolic disorders is fueling the demand for peptide therapeutics for treating metabolic disorders, thereby driving the growth of the studied market.
Furthermore, the technological development and introduction of new peptide therapeutics for treating chronic diseases like cancer are also fueling the growth of the studied market. In May 2021, ISSAR Pharmaceuticals decided to license out its peptide-based new NCEs with pre-IND filing and the United States patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes. Such developments are driving the growth of the studied market.
Therefore, the studied market is expected to witness significant growth over the forecast period due to the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.
Peptide Therapeutics Market Trends
Cancer Segment Expected to Witness Significant Growth
The cancer segment is expected to witness significant growth over the forecast period. Peptide therapeutics are targeted in drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. Factors such as the growing burden of cancer, the launch of products, and research and development are driving the segment's growth.The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment. For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed in the US in 2022. Thus, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period.
Furthermore, technological developments and new product launches are fueling the studied market's growth. In March 2022, BioNTech SE reported the expansion of its strategic collaboration with Regeneron to advance the Company's FixVaccandidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced NSCLC.
Moreover, the funding and investments for developing cancer vaccines are fueling this segment's growth. In September 2022, the Gastro-Intestinal Research Foundation (GIRF) in Chicago granted ElicioTherapeutics a USD 2.8 million grant to fund research for two therapeutic cancer vaccines. ELI-007 is being developed to target BRAF gene mutations, whereas ELI-008 is being designed to target p53 hotspot mutations in solid tumors, such as colorectal cancer, melanoma, and non-small cell lung cancer (NSCLC).
Thus, the segment is expected to witness significant growth over the forecast period due to the increasing number of cancer cases, technological developments, and the efficiency of peptide therapeutics in cancer treatment.
North America Expected to Witness Significant Growth
North America is expected to dominate the overall market throughout the forecast period. The market growth is due to various crucial factors, such as increased awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the developing biotechnology industry.The high incidence of diseases such as cancer, CVDs, and diabetes creates demand for new biopharmaceuticals in the country. For instance, as per the Canadian Cancer Statistics 2021 released in November 2021, an estimated 229,200 Canadians were diagnosed with cancer. Thus, such high numbers of cancer cases are creating opportunities for new peptide therapeutics in the country and driving the studied market.
The rising prevalence of chronic diseases among the Mexican population is also expected to drive the market's growth. For instance, the IDF published in December 2021 estimated 14 million adults in Mexico living with diabetes. Peptides like amide (GLP-1) are effective in diabetes treatment. This is expected to raise the demand for peptide therapeutics, thereby contributing to the growth of the market in the region over the forecast period.
Furthermore, the rising government initiatives are also driving the growth of the studied market in the region. For instance, in February 2022, the Government of Nova Scotia province reported that Nova Scotians enrolled in Pharmacare programs that will begin switching to a biosimilar version of certain biologic drugs, including some insulins and medications, for treating Crohn's disease and rheumatism. More than 10,000 Canadians have safely switched to a biosimilar as part of this initiative. The increasing population using biosimilar drugs is also expected to contribute to the growth of the market in the region.
Thus, the rising awareness levels relating to peptide therapeutic products, technological advancements due to the presence of key market players, and rising cases of chronic diseases like cancer and diabetes are driving the growth of this market in the region over the forecast period.
Peptide Therapeutics Market Competitor Analysis
The peptide therapeutics market is highly competitive and fragmented, consisting of several major players. Some of the companies currently dominating the market are Eli Lilly and Company, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, Novo Nordisk AS, Novartis AG, Zealand Pharma AG, and SELLAS Life Sciences Group (Galena Biopharmaceuticals).Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lilly and Company
- Amgen Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Ever Neuro Pharma GmbH
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Novo Nordisk AS
- Novartis AG
- Zealand Pharma AG
- SELLAS Life Sciences Group (Galena Biopharmaceuticals)
Methodology
LOADING...
